Science
Guest: Harry Paul Erba, MD, PhD Although survival among younger patients with acute myeloid leukemia (AML) has improved over the past decade, older patients continue to have a poor prognosis. And since age and frailty are the primary predictors of outcome among patients with AML, Dr. Harry Erba shares how the treatment of older patients with AML may be changing. BCL2-US-00027-MCVersion 2.0, Approved November 2020